Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
| العنوان: | Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach |
|---|---|
| المؤلفون: | Edo Vellenga, Emanuele Ammatuna, Gerwin Huls, Lydia Visser, Rozemarijn S. van Rijn, Anke van den Berg, Rudolf S N Fehrmann, Mathilde Rikje Willemijn de Jong, Tom van Meerten, Arjan Diepstra, Marcel A. T. M. van Vugt |
| المساهمون: | Stem Cell Aging Leukemia and Lymphoma (SALL), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| المصدر: | PLoS ONE, 13(2):e0193098. PUBLIC LIBRARY SCIENCE PLOS ONE PLoS ONE, Vol 13, Iss 2, p e0193098 (2018) PLoS ONE |
| بيانات النشر: | Public Library of Science (PLoS), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, B Cells, Cancer Treatment, Poly (ADP-Ribose) Polymerase-1, Gene Expression, lcsh:Medicine, Cell Cycle Proteins, Genome-wide association study, CHOP, Biochemistry, IMPAIR ANTITUMOR-ACTIVITY, White Blood Cells, 0302 clinical medicine, Animal Cells, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, lcsh:Science, ANTI-CD20 MONOCLONAL-ANTIBODIES, Cancers and neoplasms, CD20, Multidisciplinary, biology, Pharmaceutics, Nuclear Proteins, Diffuse large B-cell lymphoma, Hematology, Protein-Tyrosine Kinases, CANCER, Neoplasm Proteins, 3. Good health, Nucleic acids, Cell killing, Vincristine, 030220 oncology & carcinogenesis, Lymphomas, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, Cellular Types, Research Article, medicine.drug, EXPRESSION, medicine.medical_specialty, Immune Cells, Immunology, DNA repair, 03 medical and health sciences, Drug Therapy, Cell Line, Tumor, Internal medicine, DNA-binding proteins, Genetics, medicine, Chemotherapy, Humans, NON-HODGKINS-LYMPHOMA, RITUXIMAB, Antibody-Producing Cells, Cyclophosphamide, Blood Cells, RECEPTOR, business.industry, lcsh:R, Biology and Life Sciences, Proteins, Cell Biology, DNA, Antigens, CD20, medicine.disease, Lymphoma, WEE1 KINASE, 030104 developmental biology, Doxorubicin, Drug Resistance, Neoplasm, Hematologic cancers and related disorders, biology.protein, Prednisone, lcsh:Q, INHIBITORS, business, Genome-Wide Association Study |
| الوصف: | Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs can be safely combined to improve standard therapy without antagonizing anti-CD20 efficacy. In this study, we aimed to identify rituximab compatible drug-target combinations for DLBCL. For this, we collected gene expression profiles of 1,804 DLBCL patient samples. Subsequently, we performed a guilt-by-association analysis with MS4A1 (CD20) and prioritized the 500 top-ranked CD20-associated gene probes for drug-target interactions. This analysis showed the well-known genes involved in DLBCL pathobiology, but also revealed several genes that are relatively unknown in DLBCL, such as WEE1 and PARP1. To demonstrate potential clinical relevance of these targets, we confirmed high protein expression of WEE1 and PARP1 in patient samples. Using clinically approved WEE1 and PARP1 inhibiting drugs in combination with rituximab, we demonstrated significantly improved DLBCL cell killing, also in rituximab-insensitive cell lines. In conclusion, as exemplified by WEE1 and PARP1, our CD20-based genome-wide analysis can be used as an approach to identify biological relevant drug-targets that are rituximab compatible and may be implemented in phase 1/2 clinical trials to improve DLBCL treatment. |
| وصف الملف: | application/pdf |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c3b212366b459c5bf23907c4ae6844Test https://doi.org/10.1371/journal.pone.0193098Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....63c3b212366b459c5bf23907c4ae6844 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....63c3b212366b459c5bf23907c4ae6844 793 3 unknown 793.351196289063 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....63c3b212366b459c5bf23907c4ae6844&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Edo+Vellenga%22">Edo Vellenga</searchLink><br /><searchLink fieldCode="AR" term="%22Emanuele+Ammatuna%22">Emanuele Ammatuna</searchLink><br /><searchLink fieldCode="AR" term="%22Gerwin+Huls%22">Gerwin Huls</searchLink><br /><searchLink fieldCode="AR" term="%22Lydia+Visser%22">Lydia Visser</searchLink><br /><searchLink fieldCode="AR" term="%22Rozemarijn+S%2E+van+Rijn%22">Rozemarijn S. van Rijn</searchLink><br /><searchLink fieldCode="AR" term="%22Anke+van+den+Berg%22">Anke van den Berg</searchLink><br /><searchLink fieldCode="AR" term="%22Rudolf+S+N+Fehrmann%22">Rudolf S N Fehrmann</searchLink><br /><searchLink fieldCode="AR" term="%22Mathilde+Rikje+Willemijn+de+Jong%22">Mathilde Rikje Willemijn de Jong</searchLink><br /><searchLink fieldCode="AR" term="%22Tom+van+Meerten%22">Tom van Meerten</searchLink><br /><searchLink fieldCode="AR" term="%22Arjan+Diepstra%22">Arjan Diepstra</searchLink><br /><searchLink fieldCode="AR" term="%22Marcel+A%2E+T%2E+M%2E+van+Vugt%22">Marcel A. T. M. van Vugt</searchLink> ) Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Stem Cell Aging Leukemia and Lymphoma (SALL)<br />Damage and Repair in Cancer Development and Cancer Treatment (DARE)<br />Guided Treatment in Optimal Selected Cancer Patients (GUTS) ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => PLoS ONE, 13(2):e0193098. PUBLIC LIBRARY SCIENCE<br />PLOS ONE<br />PLoS ONE, Vol 13, Iss 2, p e0193098 (2018)<br />PLoS ONE ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Public Library of Science (PLoS), 2018. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2018 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22B+Cells%22">B Cells</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Treatment%22">Cancer Treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Poly+%28ADP-Ribose%29+Polymerase-1%22">Poly (ADP-Ribose) Polymerase-1</searchLink><br /><searchLink fieldCode="DE" term="%22Gene+Expression%22">Gene Expression</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3AMedicine%22">lcsh:Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+Cycle+Proteins%22">Cell Cycle Proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Genome-wide+association+study%22">Genome-wide association study</searchLink><br /><searchLink fieldCode="DE" term="%22CHOP%22">CHOP</searchLink><br /><searchLink fieldCode="DE" term="%22Biochemistry%22">Biochemistry</searchLink><br /><searchLink fieldCode="DE" term="%22IMPAIR+ANTITUMOR-ACTIVITY%22">IMPAIR ANTITUMOR-ACTIVITY</searchLink><br /><searchLink fieldCode="DE" term="%22White+Blood+Cells%22">White Blood Cells</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Animal+Cells%22">Animal Cells</searchLink><br /><searchLink fieldCode="DE" term="%22immune+system+diseases%22">immune system diseases</searchLink><br /><searchLink fieldCode="DE" term="%22hemic+and+lymphatic+diseases%22">hemic and lymphatic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%22">Antineoplastic Combined Chemotherapy Protocols</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine+and+Health+Sciences%22">Medicine and Health Sciences</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3AScience%22">lcsh:Science</searchLink><br /><searchLink fieldCode="DE" term="%22ANTI-CD20+MONOCLONAL-ANTIBODIES%22">ANTI-CD20 MONOCLONAL-ANTIBODIES</searchLink><br /><searchLink fieldCode="DE" term="%22Cancers+and+neoplasms%22">Cancers and neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22CD20%22">CD20</searchLink><br /><searchLink fieldCode="DE" term="%22Multidisciplinary%22">Multidisciplinary</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmaceutics%22">Pharmaceutics</searchLink><br /><searchLink fieldCode="DE" term="%22Nuclear+Proteins%22">Nuclear Proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Diffuse+large+B-cell+lymphoma%22">Diffuse large B-cell lymphoma</searchLink><br /><searchLink fieldCode="DE" term="%22Hematology%22">Hematology</searchLink><br /><searchLink fieldCode="DE" term="%22Protein-Tyrosine+Kinases%22">Protein-Tyrosine Kinases</searchLink><br /><searchLink fieldCode="DE" term="%22CANCER%22">CANCER</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasm+Proteins%22">Neoplasm Proteins</searchLink><br /><searchLink fieldCode="DE" term="%223%2E+Good+health%22">3. Good health</searchLink><br /><searchLink fieldCode="DE" term="%22Nucleic+acids%22">Nucleic acids</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+killing%22">Cell killing</searchLink><br /><searchLink fieldCode="DE" term="%22Vincristine%22">Vincristine</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphomas%22">Lymphomas</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Rituximab%22">Rituximab</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphoma%2C+Large+B-Cell%2C+Diffuse%22">Lymphoma, Large B-Cell, Diffuse</searchLink><br /><searchLink fieldCode="DE" term="%22Cellular+Types%22">Cellular Types</searchLink><br /><searchLink fieldCode="DE" term="%22Research+Article%22">Research Article</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink><br /><searchLink fieldCode="DE" term="%22EXPRESSION%22">EXPRESSION</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+Cells%22">Immune Cells</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22DNA+repair%22">DNA repair</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Therapy%22">Drug Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+Line%2C+Tumor%22">Cell Line, Tumor</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22DNA-binding+proteins%22">DNA-binding proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Genetics%22">Genetics</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Chemotherapy%22">Chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22NON-HODGKINS-LYMPHOMA%22">NON-HODGKINS-LYMPHOMA</searchLink><br /><searchLink fieldCode="DE" term="%22RITUXIMAB%22">RITUXIMAB</searchLink><br /><searchLink fieldCode="DE" term="%22Antibody-Producing+Cells%22">Antibody-Producing Cells</searchLink><br /><searchLink fieldCode="DE" term="%22Cyclophosphamide%22">Cyclophosphamide</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+Cells%22">Blood Cells</searchLink><br /><searchLink fieldCode="DE" term="%22RECEPTOR%22">RECEPTOR</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3AR%22">lcsh:R</searchLink><br /><searchLink fieldCode="DE" term="%22Biology+and+Life+Sciences%22">Biology and Life Sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Proteins%22">Proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+Biology%22">Cell Biology</searchLink><br /><searchLink fieldCode="DE" term="%22DNA%22">DNA</searchLink><br /><searchLink fieldCode="DE" term="%22Antigens%2C+CD20%22">Antigens, CD20</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphoma%22">Lymphoma</searchLink><br /><searchLink fieldCode="DE" term="%22WEE1+KINASE%22">WEE1 KINASE</searchLink><br /><searchLink fieldCode="DE" term="%22030104+developmental+biology%22">030104 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22Doxorubicin%22">Doxorubicin</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Resistance%2C+Neoplasm%22">Drug Resistance, Neoplasm</searchLink><br /><searchLink fieldCode="DE" term="%22Hematologic+cancers+and+related+disorders%22">Hematologic cancers and related disorders</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eprotein%22">biology.protein</searchLink><br /><searchLink fieldCode="DE" term="%22Prednisone%22">Prednisone</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3AQ%22">lcsh:Q</searchLink><br /><searchLink fieldCode="DE" term="%22INHIBITORS%22">INHIBITORS</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Genome-Wide+Association+Study%22">Genome-Wide Association Study</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs can be safely combined to improve standard therapy without antagonizing anti-CD20 efficacy. In this study, we aimed to identify rituximab compatible drug-target combinations for DLBCL. For this, we collected gene expression profiles of 1,804 DLBCL patient samples. Subsequently, we performed a guilt-by-association analysis with MS4A1 (CD20) and prioritized the 500 top-ranked CD20-associated gene probes for drug-target interactions. This analysis showed the well-known genes involved in DLBCL pathobiology, but also revealed several genes that are relatively unknown in DLBCL, such as WEE1 and PARP1. To demonstrate potential clinical relevance of these targets, we confirmed high protein expression of WEE1 and PARP1 in patient samples. Using clinically approved WEE1 and PARP1 inhibiting drugs in combination with rituximab, we demonstrated significantly improved DLBCL cell killing, also in rituximab-insensitive cell lines. In conclusion, as exemplified by WEE1 and PARP1, our CD20-based genome-wide analysis can be used as an approach to identify biological relevant drug-targets that are rituximab compatible and may be implemented in phase 1/2 clinical trials to improve DLBCL treatment. ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1932-6203 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c3b212366b459c5bf23907c4ae6844" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c3b212366b459c5bf23907c4ae6844</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1371/journal.pone.0193098" linkWindow="_blank">https://doi.org/10.1371/journal.pone.0193098</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....63c3b212366b459c5bf23907c4ae6844 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => e0193098
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Male
[Type] => general
)
[1] => Array
(
[SubjectFull] => 0301 basic medicine
[Type] => general
)
[2] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[3] => Array
(
[SubjectFull] => B Cells
[Type] => general
)
[4] => Array
(
[SubjectFull] => Cancer Treatment
[Type] => general
)
[5] => Array
(
[SubjectFull] => Poly (ADP-Ribose) Polymerase-1
[Type] => general
)
[6] => Array
(
[SubjectFull] => Gene Expression
[Type] => general
)
[7] => Array
(
[SubjectFull] => lcsh:Medicine
[Type] => general
)
[8] => Array
(
[SubjectFull] => Cell Cycle Proteins
[Type] => general
)
[9] => Array
(
[SubjectFull] => Genome-wide association study
[Type] => general
)
[10] => Array
(
[SubjectFull] => CHOP
[Type] => general
)
[11] => Array
(
[SubjectFull] => Biochemistry
[Type] => general
)
[12] => Array
(
[SubjectFull] => IMPAIR ANTITUMOR-ACTIVITY
[Type] => general
)
[13] => Array
(
[SubjectFull] => White Blood Cells
[Type] => general
)
[14] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => Animal Cells
[Type] => general
)
[16] => Array
(
[SubjectFull] => immune system diseases
[Type] => general
)
[17] => Array
(
[SubjectFull] => hemic and lymphatic diseases
[Type] => general
)
[18] => Array
(
[SubjectFull] => Antineoplastic Combined Chemotherapy Protocols
[Type] => general
)
[19] => Array
(
[SubjectFull] => Medicine and Health Sciences
[Type] => general
)
[20] => Array
(
[SubjectFull] => lcsh:Science
[Type] => general
)
[21] => Array
(
[SubjectFull] => ANTI-CD20 MONOCLONAL-ANTIBODIES
[Type] => general
)
[22] => Array
(
[SubjectFull] => Cancers and neoplasms
[Type] => general
)
[23] => Array
(
[SubjectFull] => CD20
[Type] => general
)
[24] => Array
(
[SubjectFull] => Multidisciplinary
[Type] => general
)
[25] => Array
(
[SubjectFull] => biology
[Type] => general
)
[26] => Array
(
[SubjectFull] => Pharmaceutics
[Type] => general
)
[27] => Array
(
[SubjectFull] => Nuclear Proteins
[Type] => general
)
[28] => Array
(
[SubjectFull] => Diffuse large B-cell lymphoma
[Type] => general
)
[29] => Array
(
[SubjectFull] => Hematology
[Type] => general
)
[30] => Array
(
[SubjectFull] => Protein-Tyrosine Kinases
[Type] => general
)
[31] => Array
(
[SubjectFull] => CANCER
[Type] => general
)
[32] => Array
(
[SubjectFull] => Neoplasm Proteins
[Type] => general
)
[33] => Array
(
[SubjectFull] => 3. Good health
[Type] => general
)
[34] => Array
(
[SubjectFull] => Nucleic acids
[Type] => general
)
[35] => Array
(
[SubjectFull] => Cell killing
[Type] => general
)
[36] => Array
(
[SubjectFull] => Vincristine
[Type] => general
)
[37] => Array
(
[SubjectFull] => 030220 oncology & carcinogenesis
[Type] => general
)
[38] => Array
(
[SubjectFull] => Lymphomas
[Type] => general
)
[39] => Array
(
[SubjectFull] => Female
[Type] => general
)
[40] => Array
(
[SubjectFull] => Rituximab
[Type] => general
)
[41] => Array
(
[SubjectFull] => Lymphoma, Large B-Cell, Diffuse
[Type] => general
)
[42] => Array
(
[SubjectFull] => Cellular Types
[Type] => general
)
[43] => Array
(
[SubjectFull] => Research Article
[Type] => general
)
[44] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
[45] => Array
(
[SubjectFull] => EXPRESSION
[Type] => general
)
[46] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[47] => Array
(
[SubjectFull] => Immune Cells
[Type] => general
)
[48] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[49] => Array
(
[SubjectFull] => DNA repair
[Type] => general
)
[50] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[51] => Array
(
[SubjectFull] => Drug Therapy
[Type] => general
)
[52] => Array
(
[SubjectFull] => Cell Line, Tumor
[Type] => general
)
[53] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[54] => Array
(
[SubjectFull] => DNA-binding proteins
[Type] => general
)
[55] => Array
(
[SubjectFull] => Genetics
[Type] => general
)
[56] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[57] => Array
(
[SubjectFull] => Chemotherapy
[Type] => general
)
[58] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[59] => Array
(
[SubjectFull] => NON-HODGKINS-LYMPHOMA
[Type] => general
)
[60] => Array
(
[SubjectFull] => RITUXIMAB
[Type] => general
)
[61] => Array
(
[SubjectFull] => Antibody-Producing Cells
[Type] => general
)
[62] => Array
(
[SubjectFull] => Cyclophosphamide
[Type] => general
)
[63] => Array
(
[SubjectFull] => Blood Cells
[Type] => general
)
[64] => Array
(
[SubjectFull] => RECEPTOR
[Type] => general
)
[65] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[66] => Array
(
[SubjectFull] => lcsh:R
[Type] => general
)
[67] => Array
(
[SubjectFull] => Biology and Life Sciences
[Type] => general
)
[68] => Array
(
[SubjectFull] => Proteins
[Type] => general
)
[69] => Array
(
[SubjectFull] => Cell Biology
[Type] => general
)
[70] => Array
(
[SubjectFull] => DNA
[Type] => general
)
[71] => Array
(
[SubjectFull] => Antigens, CD20
[Type] => general
)
[72] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[73] => Array
(
[SubjectFull] => Lymphoma
[Type] => general
)
[74] => Array
(
[SubjectFull] => WEE1 KINASE
[Type] => general
)
[75] => Array
(
[SubjectFull] => 030104 developmental biology
[Type] => general
)
[76] => Array
(
[SubjectFull] => Doxorubicin
[Type] => general
)
[77] => Array
(
[SubjectFull] => Drug Resistance, Neoplasm
[Type] => general
)
[78] => Array
(
[SubjectFull] => Hematologic cancers and related disorders
[Type] => general
)
[79] => Array
(
[SubjectFull] => biology.protein
[Type] => general
)
[80] => Array
(
[SubjectFull] => Prednisone
[Type] => general
)
[81] => Array
(
[SubjectFull] => lcsh:Q
[Type] => general
)
[82] => Array
(
[SubjectFull] => INHIBITORS
[Type] => general
)
[83] => Array
(
[SubjectFull] => business
[Type] => general
)
[84] => Array
(
[SubjectFull] => Genome-Wide Association Study
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Edo Vellenga
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Emanuele Ammatuna
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gerwin Huls
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lydia Visser
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rozemarijn S. van Rijn
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Anke van den Berg
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rudolf S N Fehrmann
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mathilde Rikje Willemijn de Jong
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tom van Meerten
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Arjan Diepstra
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcel A. T. M. van Vugt
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Stem Cell Aging Leukemia and Lymphoma (SALL)
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Damage and Repair in Cancer Development and Cancer Treatment (DARE)
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Guided Treatment in Optimal Selected Cancer Patients (GUTS)
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 28
[M] => 02
[Type] => published
[Y] => 2018
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 19326203
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 13
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => PLOS ONE
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |